Stay updated with breaking news from Nasdaq Imab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
I-Mab (NASDAQ:IMAB – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research report issued on Friday, Benzinga reports. They currently have a $6.00 target price on the stock. Needham & Company LLC’s price objective suggests a potential upside of 231.49% from the stock’s previous […]
I-Mab (NASDAQ:IMAB – Get Free Report) and Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. Institutional & Insider Ownership 22.6% of I-Mab shares are […]
Cantor Fitzgerald restated their overweight rating on shares of I-Mab (NASDAQ:IMAB – Free Report) in a research report report published on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for I-Mab’s FY2023 earnings at ($1.85) EPS and FY2024 earnings at ($1.14) EPS. Separately, Needham & Company LLC dropped their price target on shares of […]
I-Mab (NASDAQ:IMAB – Free Report) had its price objective lowered by Needham & Company LLC from $24.00 to $23.00 in a report published on Monday, Marketbeat.com reports. The firm currently has a buy rating on the stock. Several other brokerages have also recently issued reports on IMAB. HC Wainwright lowered their price target on shares […]
I-Mab (NASDAQ:IMAB – Free Report) had its target price decreased by HC Wainwright from $25.00 to $18.00 in a report issued on Friday morning, Marketbeat reports. HC Wainwright currently has a buy rating on the stock. Separately, Needham & Company LLC restated a buy rating and issued a $24.00 price objective on shares of I-Mab […]